Oragenics to Participate in the World Vaccine Congress Washington




Oragenics to Participate in the World Vaccine Congress Washington

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.

Ms. Murphy will be holding meetings to highlight the company’s lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, and to explore partnering opportunities. Oragenics recently reported favorable toxicology results confirming a safety and immunogenicity profile for NT-CoV2-1 that support plans to submit regulatory filings to proceed to a Phase 1 clinical study. Oragenics believes an intranasal COVID-19 vaccine holds several potential benefits compared with injectable vaccines, including targeting mucosal immunity, reducing transmission and offering a needle-free alternative for patients.

“I am excited to take part in the World Vaccine Congress this year and share our progress toward a highly differentiated intranasal COVID-19 vaccine,” said Ms. Murphy. “We expect strong interest among vaccine experts in this unique program and look forward to advancing to Phase 1 clinical trials in humans.”

Please contact tpatel@lhai.com or kmurphy@oragenics.com if you are interested in scheduling a meeting.

Earlier this month Oragenics entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301. The company is currently evaluating formulation options for NT-CoV2-1 and is assessing various regulatory pathways to advance this program efficiently and thoughtfully.

In December 2022 Oragenics reported no toxicity signals or adverse events from its GLP toxicology study in rabbits evaluating the safety and immunogenicity of NT-CoV2-1. The study objectives were to evaluate potential toxicity following repeated intranasal administration at the maximal dose anticipated to be used in humans, and to confirm the immunogenicity of the vaccine.

Oragenics previously published positive preclinical data in Scientific Reports, a Nature journal, demonstrating that intranasal administration of NT-CoV2-1 induced robust antigen-specific IgG and IgA titers in the blood and lungs of mice, and reduced viral load below the limit of detection in a hamster SARS-CoV-2 challenge model. In both mice and hamsters, the antibodies had strong neutralizing activity, preventing the cellular binding of the viral spike protein based on the ancestral reference strain and variants of concern.

About the World Vaccine Congress

The World Vaccine Congress is the largest, most established meeting dedicated to vaccines. From basic research to commercial manufacture, this one meeting covers the entire vaccine value chain where science, government and manufacturers all come together to create groundbreaking progress.

About Oragenics, Inc.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: the Company’s ability to obtain necessary funding, non-dilutive or otherwise, for the development of the vaccine and lantibiotic product candidates; the Company’s ability to advance the development of its vaccine candidate and lantibiotics candidate under the timelines and in accord with the milestones it projects; the regulatory application process, research and development stages, and future clinical data and analysis relating to vaccines and lantibiotics, including any meetings, decisions by regulatory authorities, such as the FDA and Canadian regulatory authorities and investigational review boards, whether favorable or unfavorable; the potential application of our vaccine candidate to variants and other coronaviruses; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection and license agreements; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments and demand for vaccines and antibiotics; the Company’s expectations as to the outcome of preclinical studies, nasal administration, transmission, manufacturing, storage and distribution; other potential adverse impacts such as delays in regulatory review, manufacturing delays and supply chain issues, adverse impacts on healthcare systems and disruption of the global economy; the ability to sustain compliance with our exchange listing requirements; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

Contacts

Oragenics, Inc.
Janet Huffman, Chief Financial Officer

813-286-7900

jhuffman@oragenics.com

LHA Investor Relations
Tirth T. Patel

212-201-6614

tpatel@lhai.com

C2N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research




C2N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research

Study addresses the use of pre-specified cut-off values, one of the EU/US/Clinical Trials in Alzheimer’s Disease (CTAD) Task Force key recommendations

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers—C₂N Diagnostics today announced the Annals of Clinical and Translational Neurology has published online a new study that further demonstrates the Amyloid Probability Score (APS), used in the company’s PrecivityAD® blood test to help healthcare providers better diagnose Alzheimer’s Disease (AD), is a reliable marker of brain amyloidosis among individuals aged 60 years and older with cognitive impairment (current Intended Use population). The research also shows a person’s APS score is a potential indicator of individuals actively accumulating amyloid, a dynamic and evolving process characteristic of progressive AD pathology.

In addition, C₂N says this analysis provides confirmatory evidence that the previously established APS cutoff values have high diagnostic performance when used across different cohorts. In the Intended Use population for the PrecivityAD blood test, sensitivity for identifying amyloid presence by amyloid PET imaging was ~85% (95% confidence interval [CI] of ~73-92%) and specificity was 96% (95% CI of 81-99%) after excluding the ~14% of patients that fell into an intermediate APS group population for which the test is considered non-informative. The exploratory analyses demonstrated the APS model retained strong diagnostic performance even among healthy individuals. These findings support further studies to evaluate the PrecivityAD test as a future potential screening test in cognitively unimpaired individuals (high risk) for whom biomarker testing outside of the clinical research context might be warranted.

The company says the study helps to address one of the EU/US/Clinical Trials in Alzheimer’s Disease (CTAD) Task Force key recommendations that prioritizes validation of established cut-off values using independent clinical datasets in the Intended Use population.

Researchers analyzed the diagnostic performance of the PrecivityAD blood test in a group of 200 Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) study participants, who were either cognitively impaired or healthy controls, and for whom a blood sample and amyloid PET imaging were available.

“Congratulations to the research team members for providing important findings that add to our field’s understanding of the potential role for using high performance blood biomarkers in routine clinical care for patients with cognitive impairment. This publication impressively brings the number of Precivity-related biomarker measures we have reported through peer-reviewed publications to approximately 10,000. A major unmet need exists for a non-invasive, convenient and easy-to-access method for evaluating patients for Alzheimer’s Disease as a reliable alternative to cerebrospinal fluid (CSF) and amyloid PET,” said Dr. Joel Braunstein, C₂N’s CEO and a co-author of the publication. “The PrecivityAD blood test addresses this unmet need as a CLIA validated laboratory developed test available for use by healthcare providers to evaluate for the presence or absence of amyloid pathology in cognitively impaired individuals over 60 years of age.”

The Annals of Clinical and Translational Neurology published research is available at https://precivityad.com/publications.

About C₂N Diagnostics, LLC

C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C₂N strives to provide exceptional laboratory services and products in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer’s Association. For more information visit www.C2N.com.

Contacts

COMPANY CONTACT:

Joni Henderson

Director of Marketing, Outreach and Strategic Growth

C2N Diagnostics

jhenderson@c2n.com
571-355-3371

MEDIA CONTACT:

Adam Shapiro

Adam.Shapiro@ASPR.bz
202-427-3603

Tivic Health Systems, Inc. Cuts Component Manufacturing Costs by 70%, Completes Second Key Supplier Qualification




Tivic Health Systems, Inc. Cuts Component Manufacturing Costs by 70%, Completes Second Key Supplier Qualification

SAN FRANCISCO–(BUSINESS WIRE)–$TIVC #healthcare—Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has completed the supplier qualification and first article inspection of Microart Services, Inc., one of two new partners announced in Q4 of 2022.

The supplier qualification and successful first article inspection help confirm that Tivic’s production process is under statistical control and produces safe, high-quality products in compliance with Tivic’s specifications and applicable regulatory requirements.

“Working with Microart has allowed us to reduce our printed circuit board manufacturing costs by 70% and increase production capacity by 25X,” said Ryan Sabia, COO of Tivic. “We expect that this will be an accelerator for scalable growth.”

Tivic’s partnership with two new suppliers, Microart and ALOM, has resulted in:

• Up to a 30% reduction in 3PL costs
• A 40% reduction in final assembly production costs per unit
• Up to 25x increased production capacity
• An overall COGs reduction forecast for 2023 of 37%

About Tivic

Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and certain other related conditions. For more information visit https://tivichealth.com @TivicHealth.

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Given the existence of risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of certain risks and uncertainties, and other important factors, relevant to the company, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022, under the heading “Risk Factors”; its Registration Statement on S-1, filed with the SEC on October 26, 2022, and amendments thereto, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Contacts

Media Contact:
Kayleigh Westerfield

949-632-3439

Kayleigh.Westerfield@tivichealth.com

Investor Contact:
Hanover International, Inc.

ir@tivichealth.com

Portal Innovations Expands to South Boston




Portal Innovations Expands to South Boston

Partners with ZoE Life Sciences / Beacon Capital to Operate State-of-the-Art Lab Space and Invest in Bioscience Startups at Southline

CHICAGO & BOSTON–(BUSINESS WIRE)–Portal Innovations, a leading life sciences venture development engine, announced today that it will be expanding its operations to South Boston in April, 2023. The Company, which specializes in early-stage life sciences venture creation and investments, will be launching its initial lab and office space in the Southline Boston building.

“We are excited to bring our unique business model to an emerging part of the Boston life science ecosystem,” said John Flavin, Founder and CEO of Portal Innovations. “Boston is home to world-class universities, premier life sciences venture capital firms, and an unsurpassed pool of diverse talent. Portal is eager to support entrepreneurs and founders by providing its Crafted Capital model of seed capital investment, access to strategic lab space, and management expertise to de-risk these early-stage ventures.”

Portal’s initial space at Southline Boston will consist of 22,000 SF of high-end wet lab and office space to facilitate growth for companies fundraising between Seed to Series B rounds, and will expand its footprint to 58,000 SF in the first half of 2024. Portal is partnering with Boston-based Beacon Capital and ZoE Life Sciences in a joint venture to build out the space and invest in promising life sciences companies.

“Massachusetts is unmatched in its life sciences research and development, and we join in Portal’s excitement about the promise that Boston’s neighborhoods bring to growing the industry and supporting innovation,” said Jason Cordeiro, MassBio Chief Operating Officer. “Southline Boston and Portal’s new space will deliver more opportunities for emerging biotech entrepreneurs and startups to advance their patient-driven science, be successful in their business, and contribute to the larger ecosystem.”

The Southline project is located in the former Boston Globe building off of the JFK/UMass Red Line “T” stop, near I-93, providing members with a variety of transportation options across the city.

“Boston is the leading hub for biomedical innovation and we’re thrilled to partner with Portal to support early-stage venture firms and their portfolio companies,” said Fred Seigel, CEO of Beacon Capital. “Offering a fully developed life sciences ecosystem in a single building will catalyze the next phase of Boston’s impact on life sciences.”

The entire Southline project will encompass over 700,000 square feet, primarily dedicated to opening an attractive option for life sciences companies starting and scaling in the South Boston area. The project has a food hall, gym, roof deck, brewpub, and a number of other amenities with a campus vibe, seeking to attract world-class biosciences talent in the area.

Portal Innovations is a premier venture development engine with a presence in Chicago, Atlanta, and Boston, that bridges scientific ideation in life sciences through commercial proof of concept by delivering Crafted Capital, including seed funding, specialized equipment, lab space, and management expertise to high-potential early-stage companies.

Beacon Capital Partners (“Beacon”) is a leading private real estate investment firm, owning and operating office and life science properties. The firm has a 75-year legacy of successful real estate development, management, and transformation of workplaces. For more information, please visit www.beaconcapital.com.

Contacts

For more information, please visit www.portalinnovations.com.

Media Contact: Nick Pennebaker, Director of Marketing

Media Email: nick.pennebaker@portalinnovations.com
To Apply to Portal Innovations Membership: http://23230704.hs-sites.com/portal-boston

Biotech and Healthcare Skills Funding Welcomed In Budget 2023




Biotech and Healthcare Skills Funding Welcomed In Budget 2023

OTTAWA, Ontario–(BUSINESS WIRE)–#HR–BioTalent Canada applauds the renewed commitment and investments made to skills in the country’s biotech and healthcare sectors in Budget 2023.

The $197.7 million in the budget that has been allocated to Canada’s Student Work Placement Program (SWPP) in fiscal year 2024-25 will help particularly to stem a shortfall of 65,000 workers that are needed to sustain this country’s biotechnology and healthcare sectors.

While the successful federal program has not been made permanent, its continuation will be pivotal to getting Canada’s small and medium-sized biotech employers the talent they require.

“The continuity of the Student Work Placement Program is sorely needed,” says Rob Henderson, President and CEO of BioTalent Canada. “The funds will help encourage young talent to enter an industry that remains an engine of the Canadian economy. The next step that should be taken as soon as possible is to make the program a permanent fixture in Canada’s national skills and training strategy,” he said.

Canadians saw first-hand the importance of the biotechnology sector during the Covid-19 pandemic as cutting-edge bioscience organizations led the development of lifesaving vaccines and therapeutics. Student internships will remain an essential part of the national talent strategy if the industry continues on its path to bring vaccine biomanufacturing back to Canada.

Despite its critical importance to the economy and society, Canada’s biotech industry faces a shortage of skilled workers. By 2029, that shortfall is expected to exceed 65,000 biotech workers nationwide.

BioTalent Canada has been working to alleviate this deficit through its participation in the Student Work Placement Program, having placed more than 11,000 students with leading biotechnology and healthcare organizations since 2017.

Students who participate in the program gain valuable training and workplace learning, while participating companies get access to bright minds and the leaders of tomorrow. Statistics indicate that the SWPP has been a win-win for both students and employers.

Surveys also show that SWPP is helping to drive innovation and economic growth throughout Canada, and ensuring all Canadians live healthier lives through bio-health innovations and new medical treatments. This is at a time when the federal government is investing heavily to bring the domestic production of vaccines back to Canada. Thirty percent (30%) of employers would not have created the positions without support from the Student Work Placement Program, while 40% of organizations were unsure whether the position would have been created at all.

BioTalent Canada’s Biosciences and Healthcare Student Work Placement Program has also contributed to the health of Canadians, notably with the advancement of clean technologies through the bio-energy and agri-bio sub-sectors.

The new money allocated in Budget 2023 ensures that BioTalent Canada can continue creating quality work integrated learning opportunities for students, and that they will continue to gain important real-life work experience that is needed for them to transition into the workforce.

“SWPP has helped position young talent for success in their chosen field,” says Henderson. “We are pleased to see this recognized this and the importance of continuing to grow Canada’s biotech sector prioritized.”

Rob Henderson is available for comment on Budget 2023.

About BioTalent Canada:

BioTalent Canada supports the people behind life-changing science. Trusted as the go-to source for labour market intelligence, BioTalent Canada guides bio-economy stakeholders with evidence-based data and industry-driven standards. BioTalent Canada is focused on igniting the industry’s brainpower, bridging the gap between job-ready talent and employers, and ensuring the long-term agility, resiliency, and sustainability of one of Canada’s most vital sectors.

Recently named one of the 50 Best Workplaces in Canada with under 50 employees, a Best Workplaces™ for Mental Wellness, Healthcare, and a Great Place to Work® for 2022, BioTalent Canada practices the same industry standards it recommends to stakeholders. These distinctions were awarded to BioTalent Canada following a thorough and independent survey analysis conducted by Great Place to Work®.

For more information, please visit biotalent.ca.

Contacts

Media Inquiries:
Siobhan Williams

Vice-President Marketing and Communications

BioTalent Canada

613-235-1402 ext. 229

swilliams@biotalent.ca

Cardio Diagnostics Holdings, Inc Sponsors Becker’s Hospital Review 13th Annual Meeting




Cardio Diagnostics Holdings, Inc Sponsors Becker’s Hospital Review 13th Annual Meeting

CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 13th Annual Meeting. The conference is taking place next week, April 3-6, 2023, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, the Company is further introducing their recently launched test, PrecisionCHD, at booth #300.

Becker’s Hospital Review conferences are among the healthcare industry’s leading events covering hospital leaders’ business, operational and patient-centered concerns. This annual meeting will bring together over 420 elite hospital and health system executives.

Cardio Diagnostics’ mission is to help clinicians better detect and treat cardiovascular disease, the leading cause of death in the United States. At the core of its cardiovascular solutions is a proprietary Integrated Genetic-Epigenetic Engine™ created by company founders Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D. This technology enables the development of a series of tests for precision prevention and early detection and assists in the personalized treatment of major types of cardiovascular diseases and associated co-morbidities including the already launched Epi+Gen CHD and PrecisionCHD tests. The company will also display Actionable Clinical Intelligence™, a platform for healthcare providers connecting the underlying DNA methylation and single nucleotide polymorphism biomarkers measured by this test to coronary heart disease (CHD).

“We are thrilled to sponsor Becker’s Hospital Review 13th Annual Meeting and participate in this important event for hospital and health system executives,” said Meesha Dogan, Ph.D., CEO of the Company. “This is a great opportunity to share our insights on how we are partnering with leading healthcare organizations to deploy our precision molecular cardiovascular medicine technologies that can bend the heart disease curve, help lower costs and improve patient care with a focus on our most recent product launched, PrecisionCHD.”

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “should,” “believe,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™ and PrecisionCHD™ tests are accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to execute our growth strategy and ability to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Contacts

Investors:

Gene Mannheimer

Investor Relations

855-226-9991

investors@cardiodiagnosticsinc.com

Media & Public Relations:

Khullani Abdullahi

pr@cardiodiagnosticsinc.com

Cystic Fibrosis Foundation Announces Kathryn Brown as Next Chief Communications and Marketing Officer




Cystic Fibrosis Foundation Announces Kathryn Brown as Next Chief Communications and Marketing Officer

Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science

BETHESDA, Md.–(BUSINESS WIRE)–Today, the Cystic Fibrosis Foundation announced that Kathryn Brown will join the organization as its next Chief Communications and Marketing Officer. She will oversee strategic communications and marketing across the Foundation, including initiatives to inform and engage the cystic fibrosis community, as it accelerates its mission to find a cure for the progressive, rare, genetic disorder.

Brown comes to the Foundation from the Howard Hughes Medical Institute (HHMI), a biomedical research and philanthropic organization, where she has served as Chief of Communications since 2017. In her role, she was responsible for a wide scope of communications functions, including managing both internal and external communications, and overseeing a team of more than 20 staff.

“Kathryn has a demonstrated track record of serving as an innovative thought partner, and her strategic leadership will be critical as we enter this next era of cystic fibrosis,” said Michael Boyle, MD, president and CEO of the Cystic Fibrosis Foundation. “As our efforts to advance research, science, and care evolve to meet the changing needs of people with CF, I am confident that Kathryn is well-positioned to lead our talented team in driving critical engagement with our community and our partners, as well as continuing to share one of the most amazing stories in medicine with the broader public.”

As Chief Communications and Marketing Officer, Brown will lead efforts to amplify the Foundation’s mission, strategic priorities, and value to key audiences. An essential collaborator with other senior leaders, she will help identify ways to support and strengthen the CF community. Brown will also direct internal and external communications, brand management, digital communications and website management, social media and marketing, creative design and production, media relations, and several other areas.

“I’m thrilled to join the CF Foundation and for the opportunity to work with the entire CF community, as we search for a cure and work to ensure that everyone with cystic fibrosis can live long, fulfilling lives,” said Kathryn Brown. “The Foundation is poised to continue making bold leaps forward so that one day in the future, not a single person will lose a life or loved one to CF. I’m honored to join the Foundation in our journey toward that day.”

Prior to joining HHMI in 2013, Brown was vice president of marketing and communications at the Conservation Fund and worked as a communications consultant to HHMI, the National Academies, and other leading science institutions. An award-winning writer, she is a former contributing correspondent for Science and has written for Scientific American, Discover, Popular Science, New Scientist, and other media outlets. She holds a B.A. in journalism and psychology from the University of Missouri and also serves as a trustee of the Association of Independent Research Institutes.

Brown will join the Cystic Fibrosis Foundation as Chief Communications and Marketing Officer on April 24, 2023.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, visit cff.org.

Contacts

Dee Donavanik

Email: ddonavanik@cff.org
Phone: 240-482-2857

Compass Group and AstraZeneca Expand Activities Focused on Innovation and Shared Success




Compass Group and AstraZeneca Expand Activities Focused on Innovation and Shared Success

New Facilities Management Engagement Rooted in Award-Winning ‘Vested’ Model

CHARLOTTE, N.C.–(BUSINESS WIRE)–Continuing a shared commitment to innovation, Compass Group, the world’s largest food and facility services company, and AstraZeneca, the global, science-led, patient-focused pharmaceutical company, are taking supplier management to the next level. The two companies have established a new, forward-thinking partnership for integrated facilities management that is focused on workplace experience. It expands the current scope of work, including hard and soft services, as well as foodservice, in all of AstraZeneca’s North American facilities. This transformative partnership is based on the principles of the “Vested” contracting model that builds on work the University of Tennessee has done with the U.S. Air Force and paves the way for a new approach to supplier-buyer management.

“What makes this partnership unique is that it moves away from traditional transactional activities and focuses on shared desired outcomes – effectively moving from a ‘me’ to ‘we’ approach,” said Jim Baillargeon, North American Integrated Facilities Management Lead, AstraZeneca. “All of the work we’re doing is focused on equal benefits for both organizations while also enhancing AstraZeneca’s facilities and having a more positive impact on our people, patients and planet.”

Over the past year, the Compass Group and AstraZeneca teams participated in many workshops and stakeholder alignment sessions to set the foundation for this new partnership rooted in the Vested principles from the award-winning research at the University of Tennessee College of Business Administration. Vested is a business model, methodology and mindset for creating highly collaborative, win-win business relationships in which both parties are equally committed to each other’s success. When applied, a Vested approach fosters an environment that sparks innovation, resulting in improved service, reduced costs and value that didn’t exist before – for both parties.

For more than 15 years, Compass Group has been a trusted and high-performing supplier to AstraZeneca, and this expanded partnership will contribute to the next generation workplace experience. This includes prioritizing diversity and inclusion, sustainability, technology, health and well-being, and community outreach – all aligning with AstraZeneca and Compass Group values. The Compass Group team recently renewed the WELL Health-Safety Rating for the Gaithersburg campus, a certification that was facilitated on AstraZeneca’s behalf in 2021.

“We are committed to creating a unique and healthy workplace that enables productivity and innovation,” said Oliver Sach, Senior Vice President, Compass Group. “This partnership is on the leading edge of workplace experience, showing that Integrated Facilities Management brings direct value to AstraZeneca and their employees. Compass Group’s hospitality and solutions-focused culture will ensure the vision of this Vested partnership becomes a reality.”

“Being innovative and collaborative is inherent in how both AstraZeneca and Compass Group operate, but each company’s commitment to the Vested model is another example of how they are creating a next generation partnership that goes well beyond a traditional vendor-client relationship,” said Kate Vitasek, University of Tennessee faculty member and architect of the Vested business model. “Because the Vested model is built to transform business relationships, the partnership value increases exponentially and paves the way for long-term, shared success.”

About Compass Group North America

Compass Group is redefining the food and facility services landscape with innovation and passion through the lens of what’s next. Serving premier healthcare systems, respected educational institutions, world-renowned cultural centers, popular sporting and entertainment venues, and Fortune 500 organizations the world over, Compass Group always finds a way to deliver excellence in nearly any vertical. Ranked No. 1 by industry peers on Fortune’s 2020 list of World’s Most Admired Companies, Compass has also earned a spot on Forbes’ list of the Best Employers for Diversity in 2020 and is among the Top 50 Companies Changing the World according to Fortune. Learn more about the Compass experience at www.compass-usa.com.

Contacts

Lisa Claybon, Compass Group, lisa.claybon@compass-usa.com

Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date




Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #LinearDNA—Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was produced by the Company’s LinearDNA™ platform under a large recurring purchase order with a global manufacturer of in vitro diagnostics that was announced in the first quarter of fiscal 2023 and is the largest single shipment of linearDNA to date. The Company expects to ship a final multi-gram quantity in the third fiscal quarter of 2023 to fulfill the purchase order earlier than contractually stipulated.

“We believe that this production milestone underscores our LinearDNA platform’s capacity for the rapid, enzymatic production of DNA at very large scale that stands in stark contrast to the scalability bottlenecks and challenges associated with conventional plasmid DNA to support both high value biotherapeutic and lower price-point diagnostic applications,” stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences. “Building on our platform’s inherent advantages of speed and scale, we are concurrently pursuing platform optimizations and a timeline to cGMP (current Good Manufacturing Practices) that we believe will enhance linearDNA’s standing as an alternative source of DNA. The future of our LinearDNA platform will have it supplying the needs of the entire DNA demand curve, from GLP-grade (Good Laboratory Practices) product for in vitro diagnostics and biotherapeutic research and development to cGMP-grade, therapeutic DNA as a direct replacement for plasmid DNA-reliant nucleic acid-based therapies.”

The Company’s LinearDNA platform is focused on empowering the next generation of nucleic acid-based therapies. The platform uses a cell-free, enzymatic approach that confers the advantages of simplicity, purity, speed, flexibility, and scalability in a fractional footprint relative to conventional plasmid DNA (fermentation)-based manufacturing processes. The resultant DNA, known as linearDNA™, is currently produced at GLP-grade in volumes from micrograms to grams to support customers’ needs. The Company is pursuing a timeline for cGMP linearDNA production that will enable it to support customers from research and development and drug discovery through large-scale manufacturing for clinical trials and commercial use. Learn more about linearDNA at www.linearrxdna.com

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using PCR to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under the ticker symbol ‘APPDW.’

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from any customer order for linearDNA or any linearDNA-based therapeutic, whether any of Applied DNA’s or its customers therapeutic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval as therapeutic products from the FDA, the USDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 14, 2022, as amended, its Form 10-Q filed on February 9, 2023, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts

Corporate:
Investor Relations Contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
LineaRx/LinearDNA Platform Contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com
Web: www.adnas.com
Twitter: @APDN

Baxter to Host Annual Meeting of Stockholders in Virtual Format




Baxter to Host Annual Meeting of Stockholders in Virtual Format

DEERFIELD, Ill.–(BUSINESS WIRE)–$BAX–Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2023 Annual Meeting) in a virtual format on Tuesday, May 2, 2023 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the meeting. Online access to the meeting will begin at 8:30 a.m., Central Time. Stockholders will not be able to attend the meeting in person. If you plan to attend the virtual meeting, please check https://investor.baxter.com for updates prior to the meeting date.

As always, whether or not you plan to attend the virtual 2023 Annual Meeting, you are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials for the meeting. If you have already voted, you do not need to vote again.

Attending the Virtual Meeting

You can attend the meeting by accessing www.virtualshareholdermeeting.com/BAX2023 and entering the 16-digit control number on the proxy card or notice of availability of proxy materials you previously received; if you hold your shares in “street name” (i.e., through an account at a broker or other nominee), please follow your broker’s or nominee’s instructions you previously received to obtain your 16-digit control number or otherwise attend through the broker or nominee.

A list of Baxter’s stockholders of record will be available for examination by stockholders on the meeting website during the meeting.

Asking Questions

If you wish to submit a question, you may do so in two ways. If you want to ask a question before the meeting, then beginning at 9 a.m., Central Time, on April 28, 2023, and until 11:59 p.m., Central Time, on May 1, 2023, you may log into www.proxyvote.com and enter your 16-digit control number. Once past the login screen, click on “Question for Management,” type in your question and click “Submit.” Alternatively, you will be able to submit questions live during the meeting by accessing the meeting at www.virtualshareholdermeeting.com/BAX2023, typing your question into the “Ask a Question” field and clicking “Submit.” Only questions pertinent to meeting matters will be answered during the meeting, subject to time constraints. If any questions pertinent to meeting matters cannot be answered during the meeting due to time constraints, we will post and answer a representative set of these questions online at https://investor.baxter.com. The questions and answers will be available as soon as reasonably practicable after the meeting and will remain available until one week after posting.

Voting Shares at the Virtual Meeting

If you have not voted your shares prior to the meeting, you will be able to vote your shares electronically at the 2023 Annual Meeting by clicking “Vote Here” on the meeting website. Whether or not you plan to attend the meeting, you are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials you previously received.

The proxy materials you previously received may continue to be used to vote your shares in connection with the meeting. If you have already voted, you do not need to vote again.

Attending the Virtual Meeting as a Guest

If you would like to attend the meeting as a guest in listen-only mode, please access www.virtualshareholdermeeting.com/BAX2023 and enter the information requested on the screen. Please note you will not have the ability to ask questions or vote during the meeting if you participate as a guest.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Baxter is a registered trademark of Baxter International Inc.

Contacts

Media Contact

Steve Brett, (224) 948-5353

media@baxter.com

Investor Contact

Clare Trachtman, (224) 948-3020